Monday 2 January 2017

Biochip Products and Services Market Analysis and Forecasts, By Product Type 2018

The high degree of rivalry between players characterizes the landscape of the U.S. biochip products and services market, finds a new study by Transparency Market Research (TMR). According to this study, the market demonstrates an oligopolistic structure and is led by Illumina Inc., Affymetrix Inc., and Life Technologies Corp. In the recent times, the count of participants in this market has significantly increased, thanks to the rise in government funding to encourage genetic research and cancer treatment. As a result, the competition within the market has intensified considerably. 

Analysts expect the competition to remain intense in the near future as a number of biochip products and services providers, based outside of the U.S. such as Technology Center Dortmund GmbH, Scienion AG, and Arrayjet Ltd., are trying to expand their reach in this market through product launches and strategic alliances. 

As per TMR, the U.S. market for biochip products and services presented an opportunity worth US$2.4 bn in 2011. The market is estimated to increase at a CAGR of 10.10% between 2012 and 2018 and reach US$4.7 bn by the end of the forecast period. Microarrays have attracted strong demand in the recent past and are likely to gain substantial momentum in the near future too. The segment is expected to hold a share of 57.4% in the overall demand for biochip products and services by 2018.


Drug Delivery to Continue to Exhibit Strong Demand for Biochip Products and Services

The report assesses this market on the basis of the key applications of biochip products and services, that is, in-vitro diagnostic testing, drug delivery, science research, forensic medicine, defense, and disease management. The drug delivery segment has emerged as the prime application area for these products and services on account of the increasing utilization of biochip technology in single nucleotide polymorphism (SNP) identification and genotyping, protein analysis, gene expression analysis, and characterization in drug delivery. The opportunity for biochip products and services in this segment is expected to reach US$2.5 bn by the end of 2018.

Rising Application of Genomics and Proteomics in Cancer Research and DNA Microarrays in Drug Delivery to Boost Market

“The increase in advanced research due to the growing prevalence of cancer and other life-threatening diseases has been fueling the demand for biochip products and services remarkably,” says the author of this report. For instance, the application of genomics and proteomics has increased significantly in cancer research activities and the demand for DNA microarrays has been gaining impetus in drug discovery over the recent past. The trend is expected to continue over the next few years, driving the U.S. market for biochip products and services remarkably.

The application of these products and services is also projected to rise in the manufacturing of personalized medicines and life-science research in the years to come, resulting in the significant growth of this market.

Costly Procedure of Biochip Production to Affect U.S. Biochip Products and Services Market

While the market exhibits strong growth prospects, the complicated and costly procedure of biochip production may obstruct its growth trajectory in the coming years. The availability of alternative technologies such as polymerase chain reactions, and mass spectrometry may also affect the market to some extent in the near future, states the report.

The study presented here is based on a report by Transparency Market Research (TMR) titled “Biochip Products and Services Market - (Microarrays, Reagents, Drug Discovery, Life Science Research, IVD Tests) U.S. Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018.”

Browse Full Research Report on Biochip Products and Services Market:
http://www.transparencymarketresearch.com/biochip-products-services.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Artificial Vital Organs and Medical Bionics Market Volume Analysis By Region 2018

The oligopolistic nature of the global artificial vital organs and medical bionics market is mainly characterized by two important factors: The low clinical success rate of artificial organs in the pipeline and the high consolidation activity, reports Transparency Market Research (TMR) in a new study. There is a limited number of players in the artificial vital organs and medical bionics market and each player prefers to operate in a niche segment of the overall market. For instance, the key players in the artificial kidney market are Baxter Healthcare, Gambro AB, Fresenius Medical Care, Nipro Europe, and Asahi Medical. 

“Implementation of high-end technology in new products that are in the pipeline is making them more compatible, durable, and safe, thus resulting in greater life expectancy of the patients, which will escalate the growth of the global artificial vital organs and medical bionics market,” says a TMR analyst. The incorporation of sophisticated technology also indicates the potential new entrants have in this market along with their key products in development.

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1271

Growing Prevalence of Organ Failure to Encourage Growth in Demand for Artificial Vital Organs 

During recent times, an increase in the number of cases associated with failure of heart, kidneys, pancreas, and lungs have increased the demand for organ replacements. To put this in perspective, various studies report that the number of patients with acute kidney failure worldwide is increasing at the rate of 7% per year. However, there is a shortage of supply with respect to the demand. The lack of availability of donor organs and bio-artificial organs has substantially increased the need to develop artificial organs.

Organ transplant is not just subjected to availability of organ but also the right match for replacement. “The shortage of suitable organs for transplant has further induced the need for sophisticated artificial organs, which would represent lifesaving technologies as bridge-to-transplant and bridge-to-recovery,” says the TMR analyst. Therefore, an increase in the incidence of organ failure and lack of donor organs is likely to drive the global artificial vital organs and medical bionics market.

Low Cost Effectiveness Detrimental to Use of Artificial Organs and Medical Bionics

Continuous technological advances in artificial organ product designs have made it difficult to redeem clear cost effectiveness. There is a high development cost associated with artificial organ development and medical bionics due to the requirement of substantial resources. The cost effectiveness issue is further intensified by the lack of satisfactory standards and methods.

Artificial organ implantation imposes physiological threats on the patient to make a conscious decision about whether to opt for an artificial organ. It is believed that transplant of an artificial organ may cause disabling injury or even death. It becomes difficult to obtain credibility with respect to artificial organs because of the immense financial, emotional and social strain exerted on caregivers of the transplant patient. All these factors collectively restrain the growth of the artificial organs market.

Artificial Vital Organs to Dominate Owing to Speedy Recovery and Enhanced Outcomes

In 2011, the valuation of the global artificial vital organs and medical bionics market US$17.48 bn and is estimated to reach US$32.32 bn by 2018. By product type, artificial vital organs segment is the leading segment and is expected to retain the same position till 2018. The segment, which was valued at US$15.66 bn in 2015, is anticipated to reach US$19.50 bn by 2018. However, with intensive and rapid technological innovation, medical bionics segment is anticipated to be a faster growing segment.

In terms of geography, North America leads the market and is anticipated to retain its leadership by the end of 2018. The valuation of the regional market is expected to reach US$12.93 bn in 2018. However, Asia Pacific will register highest growth rate owing to the increasing number of new product approvals by regulatory associations.

The information presented in this review is based on a Transparency Market Research report, titled, ‘Artificial Vital Organs and Medical Bionics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018.’

Browse Full Research Report on Artificial Vital Organs and Medical Bionics Market:
http://www.transparencymarketresearch.com/artificial-vital-organs-medical-bionics.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.